Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence
ConclusionsThe treatment of mCRPC was associated with significant cost. In the post-docetaxel setting, single fraction radiotherapy and enzalutamide were considered cost-effective in most studies. Generic ZA was the recommended bone-targeting therapy.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Docetaxel | External Beam Therapy | Health Management | Prostate Cancer | Reclast | Study | Taxotere | Zometa